Reebok oxygen claim not scientifically proven

By Admin
The Advertising Standards Agency (ASA) has ordered sportswear firm Reebok to remove an advert which it says published unsupported claims. Reebok said i...

The Advertising Standards Agency (ASA) has ordered sportswear firm Reebok to remove an advert which it says published unsupported claims.

Reebok said in a promotional leaflet that its ZigTechApparel which is “engineered with Celliant fibres” is able to increase oxygen levels in the body by up to seven percent.

The company says that this is made possible because the fibres allow infrared light that is emitted from the body to be reflected back towards it, which in turn enables capillaries to relax and increases blood flow.  

However, the ASA feels that the studies which Reebok submitted to support the claim do not offer “documentary evidence for claims capable of objective substantiation.”

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of Healthcare Global, click here

The leaflet featured F1 racing driver Lewis Hamilton who has previously been involved in advertising campaigns for Reebok, recently promoting the Reezig ZigTech trainers.

Hamilton appeared in the advertising leaflet wearing the Reezig ZigTech trainers, something which Reebok also received a warning for after the ASA said it could lead consumers to believe that the trainers have been engineered with the new technology, which they have not.

A spokesperson for Reebok said in a statement: “We accept but disagree with this ruling, which was based on one complaint about one leaflet.”

“The leaflet clearly showed the shoe on one side and the clothing on the other and, in our view, was not misleading.”

She went on to say that the Celliant fibres were a “clinically proven technology to which we remain firmly committed.”

 

Lewis Hamilton in a Reebok ZigTech advert:

Share
Share

Featured Articles

Grifols & Orange Business Launch Egypt Plasma Project

Grifols & Orange Business Complete landmark phase of Data Centre for Plasma Derivatives Facility, designed to boost healthcare in Egypt

Healthcare business roundup: Eli Lilly, Novo Nordisk, Aspen

Eli Lilly's experimental cardiovascular drug ‘promising’; Aspen Pharmacare to manufacture mpox vaccines; Novo Nordisk says Ozempic shortage ‘worsening’

Global Health Funding 'Facing Post-Pandemic Challenges'

IHME report highlights shifting priorities and economic pressures affecting global health financing, despite increase in funding since pre-COVID levels

The Merck Group: Pharma's History & Innovation in India

Medical Devices & Pharma

How CVS Health is Rising to the Omnichannel Challenge

Procurement & Supply Chain

Kinaxis: Pharma Seeing Euro-wide Supply Chain Challenges

Procurement & Supply Chain